

Application No. 09/724,940
Amendment dated September 15, 2003
Reply to Restriction/Election of Species Requirement of March 13, 2003

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1-30. (Canceled)

31. A method for preventing and/or treating an amyloid-related disease in a subject, comprising administering an antigenic amount of a peptide comprising at least one unnatural amino acid selected from the group consisting of a D-amino acid, an α , α -disubstituted amino acid, an N-alkyl amino acid, lactic acid, 4-hydroxyproline, γ -carboxyglutamate, ϵ -N,N,N-trimethyllysine, ϵ -N-acetyllysine, O-phosphoserine, N-acetylserine, N-formylmethionine, 3-methylhistidine, 5-hydroxylysine, ω -N-methylarginine, and isoaspartic acid, which elicits production of antibodies against said peptide, and elicits an immune response by said subject sufficient to prevent and/or treat said disease, wherein said antibodies and/or immune cells interact with at least one region of an amyloid protein.

32. The method of claim 31, wherein said peptide is A β peptide, an immunogenic fragment thereof, a protein conjugate thereof, an immunogenic derivative peptide thereof, or a peptidomimetic thereof.

33. The method of claim 32, wherein said peptide is comprised of at least one D-amino acid.

34. The method of claim 33, wherein said peptide is selected from the group consisting of A β 1-42, A β 1-40, A β 1-10, A β 1-12, A β 1-28, A β 13-28, A β 17-28, and A β 35-42.

35. The method of claim 34, wherein said peptide is modified by inserting one or more amino acid residues, or by substituting one or more amino acid residues with other amino acids.

Application No. 09/724,940

Amendment dated September 15, 2003

Reply to Restriction/Election of Species Requirement of March 13, 2003

36. The method of claim 31, wherein said subject is a human being.
37. The method of claim 31, wherein said disease is Alzheimer's disease.
38. (Withdrawn) A vaccine for preventing and/or treating an amyloid-related disease in a subject, comprising an antibody raised against an antigenic amount of a peptide comprising at least one unnatural amino acid selected from the group consisting of a D-amino acid, an α , α -disubstituted amino acid, an N-alkyl amino acid, lactic acid, 4-hydroxyproline, γ -carboxyglutamate, ϵ -N,N,N-trimethyllysine, ϵ -N-acetyllysine, O-phosphoserine, N-acetylserine, N-formylmethionine, 3-methylhistidine, 5-hydroxylysine, ω -N-methylarginine, and isoaspartic acid, wherein said antibody interacts with at least one region of an amyloid protein sufficient to prevent and/or treat said disease.
39. (Withdrawn) The vaccine of claim 38, wherein said peptide is A β peptide, an immunogenic fragment thereof, a protein conjugate thereof, an immunogenic derivative peptide thereof, or a peptidomimetic thereof.
40. (Withdrawn) The vaccine of claim 39, wherein said peptide is comprised of at least one D-amino acid.
41. (Withdrawn) The vaccine of claim 40, wherein said peptide is selected from the group consisting of A β 1-42, A β 1-40, A β 1-10, A β 1-12, A β 1-28, A β 13-28, A β 17-28, and A β 35-42.
42. (Withdrawn) The vaccine of claim 41, wherein said peptide is modified by inserting one or more amino acid residues, or by substituting one or more amino acid residues with other amino acids.
43. (Withdrawn) The vaccine of claim 38, wherein said subject is a human being.

Application No. 09/724,940

Amendment dated September 15, 2003

Reply to Restriction/Election of Species Requirement of March 13, 2003

44. (Withdrawn) The vaccine of claim 38, wherein said disease is Alzheimer's disease.

45. (Withdrawn) A vaccine for preventing and/or treating an amyloid-related disease in a subject, comprising an antigenic amount of a peptide comprising at least one unnatural amino acid selected from the group consisting of a D-amino acid, an α , α -disubstituted amino acid, an N-alkyl amino acid, lactic acid, 4-hydroxyproline, γ -carboxyglutamate, ϵ -N,N,N-trimethyllysine, ϵ -N-acetyllysine, O-phosphoserine, N-acetylserine, N-formylmethionine, 3-methylhistidine, 5-hydroxylysine, ω -N-methylarginine, and isoaspartic acid, which elicits an immune response by said subject sufficient to prevent and/or treat said disease.

46. (Withdrawn) The vaccine of claim 45, wherein said peptide is A β peptide, an immunogenic fragment thereof, a protein conjugate thereof, an immunogenic derivative peptide thereof, or a peptidomimetic thereof.

47. (Withdrawn) The vaccine of claim 46, wherein said peptide is comprised of at least one D-amino acid.

48. (Withdrawn) The vaccine of claim 47, wherein said peptide is selected from the group consisting of A β 1-42, A β 1-40, A β 1-10, A β 1-12, A β 1-28, A β 13-28, A β 17-28, and A β 35-42.

49. (Withdrawn) The vaccine of claim 48, wherein said peptide is modified by inserting one or more amino acid residues, or by substituting one or more amino acid residues with other amino acids.

50. (Withdrawn) The vaccine of claim 45, wherein said subject is a human being.

51. (Withdrawn) The vaccine of claim 45, wherein said disease is Alzheimer's disease.

Application No. 09/724,940

Amendment dated September 15, 2003

Reply to Restriction/Election of Species Requirement of March 13, 2003

52. (Withdrawn) A method for preventing and/or treating an amyloid-related disease in a subject, comprising administering an antibody raised against an antigenic amount of a peptide comprising at least one unnatural amino acid selected from the group consisting of a D-amino acid, an α , α -disubstituted amino acids, an N-alkyl amino acid, lactic acid, 4-hydroxyproline, γ -carboxyglutamate, ϵ -N,N,N-trimethyllysine, ϵ -N-acetyllysine, O-phosphoserine, N-acetylserine, N-formylmethionine, 3-methylhistidine, 5-hydroxylysine, ω -N-methylarginine, and isoaspartic acid, wherein said antibody interacts with at least one region of an amyloid protein sufficient to prevent and/or treat said disease.

53. (Withdrawn) The method of claim 52, wherein said peptide is A β peptide, an immunogenic fragment thereof, a protein conjugate thereof, an immunogenic derivative peptide thereof, or a peptidomimetic thereof.

54. (Withdrawn) The method of claim 53, wherein said peptide is comprised of at least one D-amino acid.

55. (Withdrawn) The method of claim 54, wherein said peptide is selected from the group consisting of A β 1-42, A β 1-40, A β 1-10, A β 1-12, A β 1-28, A β 13-28, A β 17-28, and A β 35-42.

56. (Withdrawn) The method of claim 55, wherein said peptide is modified by inserting one or more amino acid residues, or by substituting one or more amino acid residues with other amino acids.

57. (Withdrawn) The method of claim 52, wherein said subject is a human being.

58. (Withdrawn) The method of claim 52, wherein said disease is Alzheimer's disease.